This site is 100% ad supported. Please add an exception to adblock for this site.

Anticoagulants and Vitamin K


undefined, object
copy deck
- parenteral anticoagulant
- catalyzes inactivation of clotting factors by antithrombin III
- used in low doses post-op
- oral anticoagulant
- delayed action since it prevents synthesis of clotting factors
- antagonizes vitamin K
drug interactions in clotting
- phenylbutazone displaces warfarin from plasma proteins
- barbiturates stimulate metabolic inactivation of anticoagulants
- antibiotics decrease available vitamin K, increasing the effectiveness of anticoagulants
- large vitamin K doses overcome the inhibition
vitamin K
- induces the post-translational carboxylation of factors 2, 7, 9, 10, proteins C and S, prothrombin and maybe tissue factor
class 1 of platelet aggregation inhibitors
- aspirin, indomethacin, sulfinpyrazone inhibit cyclo-oxygenase and block TXA2 formation
- platelet inhibitor which increases intracellular levels of inhibitory messenger cAMP
clopidogrel and ticlopidine
reduce platelet aggregation by inhibiting the ADP pathway of platelet aggregation
abciximab, eptifibatide, tirofiban
glycoprotein IIb/IIIa inhibitors; block the final common pathway for platelet aggregation
streptokinase and urokinase
cause systemic plasmin formation, which degrades numerous circulating proteins like fibrinogen and coagulation factors
t-PA (tissue plasminogen activators)
bind tightly to fibrin and restricts its activity to vicinity of the thrombus

Deck Info